DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cf37d4/sun_pharmaceutical) has announced the addition of the "Sun Pharmaceuticals Generics Company Intelligence Report" report to their offering.
India-based Sun Pharmaceutical Industries was established in 1983, initially selling psychiatry-related products in West Bengal and Bihar. Sun has grown to be an international company with 17 manufacturing locations and a presence in 30 countries.
Group companies include the US-based Caraco Pharmaceutical Laboratories, in which Sun holds a majority stake. Caraco had sales of over US$337 million in 2008/09, but has faced regulatory issues in 2009 which has led to products being seized by the FDA.
Sun has a strong presence in cardiology, diabetes and neurology.
Sun reported annual sales in FY2008/09 worth Rs42,723 million (US$932.2 million), with total revenues worth Rs44,808.1 million (US$977.7 million). This was an increase over the prior year of 27% and 28%, respectively. Profit after tax reached Rs18,177.3 million (US$396.6 million), up by 22% over the prior year.
Since the middle of 2007, Sun has been in a battle to acquire the Israel-based Taro Pharmaceutical Industries. The effort has become increasingly bitter, and has been heard in Israel's Supreme Court. Sun finally won control of Taro in September 2010.
Key Topics Covered:
1. Executive Summary
2. Introduction
3. Products
4. Financial Results
5. Major Developments
6. Contact Details
For more information visit http://www.researchandmarkets.com/research/cf37d4/sun_pharmaceutical
Source: Espicom Business Intelligence Ltd